Comparer des méthodes
Examinez les méthodes sélectionnées côte à côte ; les lignes qui diffèrent sont mises en évidence.
| Essai clinique randomisé adaptatif× | Essai clinique de phase III× | |
|---|---|---|
| Domaine | Épidémiologie | Épidémiologie |
| Famille | Process / pipeline | Process / pipeline |
| Année d'origine≠ | Late 1990s–2000s (widespread adoption post-2010) | 1962 (Kefauver-Harris Amendment formalised phased drug development) |
| Auteur d'origine≠ | Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019 | FDA regulatory framework / ICH guidelines |
| Type≠ | Experimental clinical trial design | Confirmatory randomised controlled trial |
| Source fondatrice≠ | Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. DOI ↗ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 |
| Alias | adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial | Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT |
| Apparentées | 6 | 6 |
| Résumé≠ | An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study. | A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption. |
| ScholarGateJeu de données ↗ |
|
|